Allogene Therapeutics (ALLO) Stock News

Allogene Therapeutics (Nasdaq: ALLO) will report third quarter 2025 financial results and provide a business update on November 6, 2025 after market close. A live audio webcast and conference call is scheduled for 2:00 p.m. PT / 5:00 p.m. ET.

The listen-only webcast will be available via the company website under Investors > News and Events, and a replay will be posted for approximately 30 days. Investors who wish to ask questions must register for the conference call to receive a personal PIN to access the call.

Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotech company focused on developing allogeneic CAR T (AlloCAR T™) therapies for cancer and autoimmune diseases, has announced its participation in Citi's 2025 Biopharma Back to School Summit.

The presentation is scheduled for Wednesday, September 3, at 7:30 AM PT/10:30 AM ET. Investors can access the webcast through Allogene's website, with replays available for approximately 30 days after the event.

Allogene Therapeutics (Nasdaq: ALLO) reported Q2 2025 financial results and provided significant updates across its clinical pipeline. The company announced the advancement of its pivotal Phase 2 ALPHA3 trial for Cema-Cel in LBCL, now proceeding as a two-arm randomized study with over 50 activated sites. Additionally, Allogene initiated the Phase 1 RESOLUTION trial for ALLO-329 in autoimmune diseases and presented updated ALLO-316 results in renal cell carcinoma at ASCO 2025.

Financial highlights include a Q2 2025 net loss of $50.9 million ($0.23 per share) and a strong cash position of $302.6 million, extending runway into 2H 2027. R&D expenses were $40.2 million, while G&A expenses totaled $14.3 million for the quarter.

[ "Strong cash position of $302.6 million with runway extended into 2H 2027", "Successful expansion to over 50 clinical sites across U.S. and Canada for ALPHA3 trial", "FDA alignment achieved on pivotal trial design for ALLO-316 in solid tumors", "Launch of first autoimmune disease trial with ALLO-329" ]

Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotech company focused on developing allogeneic CAR T (AlloCAR T™) therapies for cancer and autoimmune diseases, will release its Q2 2025 financial results on August 13, 2025 after market close.

The company will host a conference call and webcast at 2:00 PM PT/5:00 PM ET on the same day. Investors can access the webcast through Allogene's website, while those wishing to ask questions during the call must register separately to receive a personal PIN.

Allogene Therapeutics (NASDAQ:ALLO) has announced a significant change in its ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma. The company will proceed with standard fludarabine and cyclophosphamide (FC) lymphodepletion regimen, discontinuing the FC plus ALLO-647 (FCA) arm following a patient death attributed to ALLO-647.

The decision was made after a Grade 5 adverse event occurred on Day 54 post-infusion, resulting from hepatic failure due to disseminated adenovirus infection. The trial will now continue as a two-arm randomized study comparing cema-cel with standard FC lymphodepletion to observation. The scheduled futility analysis remains planned for 1H 2026.

Allogene is shifting its clinical strategy, removing ALLO-647 from all trials and advancing next-generation AlloCAR T products using their proprietary Dagger® Platform Technology, designed to minimize or eliminate standard lymphodepletion needs.

Allogene Therapeutics (ALLO) presented promising Phase 1 TRAVERSE trial data for ALLO-316 in treating advanced renal cell carcinoma (RCC). The study demonstrated a 31% confirmed response rate in patients with CD70 TPS ≥50%, with four out of five confirmed responders maintaining ongoing responses, including one lasting over 12 months. The trial enrolled 22 heavily pretreated patients, with 20 receiving ALLO-316 treatment. Using the proprietary Dagger technology, patients received standard lymphodepletion followed by a single dose of 80 million AlloCAR T cells. The safety profile was manageable, with main adverse events including cytokine release syndrome (68%, no grade ≥3), neutropenia (68%), and decreased white blood cell count (68%). The treatment showed particular efficacy in patients with high CD70 expression, marking a significant advancement in allogeneic CAR T therapy for solid tumors.

Allogene Therapeutics (NASDAQ: ALLO), a clinical-stage biotech company focused on developing allogeneic CAR T (AlloCAR T™) therapies for cancer and autoimmune diseases, has announced its participation in four major investor conferences:

• TD Cowen's 6th Annual Oncology Innovation Summit (May 27, 9:30AM PT)• Jefferies Global Healthcare Conference (June 4, 1:55PM PT)• Goldman Sachs 46th Annual Global Healthcare Conference (June 10, 5:00AM PT)• Oppenheimer Innovators in I&I Summit (June 25, 9:45AM PT)

Webcasts of the presentations will be available on the company's website (www.allogene.com) under the Investors tab, with replays accessible for approximately 30 days after the events.

Allogene Therapeutics (NASDAQ: ALLO) announced two key presentations at the upcoming 2025 ASCO Annual Meeting. The first is an oral presentation featuring ALLO-316, their investigational AlloCAR T product targeting CD70 for advanced renal cell carcinoma (RCC). ALLO-316, utilizing the proprietary Dagger® technology, is notable as the first allogeneic CAR T product showing promise in solid tumors. The presentation will include updated data from the Phase 1 TRAVERSE study's expansion cohort.

Additionally, a Trial-in-Progress poster will showcase the Phase 2 ALPHA3 trial design for cemacabtagene ansegedleucel (cema-cel) in large B-cell lymphoma (LBCL). This trial evaluates cema-cel as a first-line consolidation treatment for patients who remain minimal residual disease (MRD) positive after initial chemoimmunotherapy.

Allogene Therapeutics (ALLO) reported Q1 2025 financial results and provided updates on its clinical programs. The company ended Q1 with $335.5 million in cash and reported a net loss of $59.7 million ($0.28 per share). Key developments include:

The pivotal Phase 2 ALPHA3 trial for Cema-Cel in LBCL has nearly 50 activated sites across the U.S., with over 250 patients consented for MRD screening. However, the lymphodepletion selection and futility analysis has been delayed to 1H 2026 due to site-related factors.

The company implemented cost-realignment measures to extend cash runway into 2H 2027, focusing on advancing Cema-Cel/ALPHA3 and ALLO-329/RESOLUTION trials. The RESOLUTION trial for autoimmune diseases is set to begin mid-2025, while updated Phase 1 ALLO-316 trial results in renal cell carcinoma will be presented at ASCO 2025.

2025 guidance projects a decrease in cash of approximately $150 million with GAAP operating expenses around $230 million.